|

Fish Oil, Metformin and Heart Health in PCOS

RECRUITINGPhase 1Sponsored by University of Alberta
Actively Recruiting
PhasePhase 1
SponsorUniversity of Alberta
Started2025-11-01
Est. completion2026-12-30
Eligibility
Age25 Years – 45 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06424860

Summary

Women with Polycystic Ovary Syndrome (PCOS) have high testosterone levels which is associated with altered insulin-glucose metabolism and an adverse blood lipid profile, predisposing them to the development of Type II Diabetes and Cardiovascular Disease (CVD). This study will investigate the use of dietary fish oil supplementation as a safe and effective intervention, and as an adjunct therapy to standard of care treatment with metformin to improve heart health, blood lipids and insulin-glucose metabolism in women with PCOS, and those with PCOS and Type 2 Diabetes.

Eligibility

Age: 25 Years – 45 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* diagnosis of PCOS
* overweight-obese (BMI \>25 kg/m2)
* elevated fasting plasma TG (\>150 mg/dL)
* and/or apoB48-remnant cholesterol lipoproteins (\>20 ug/ml)
* impaired insulin sensitivity (glucose 100-125 mg/dL and/or insulin \>15 (uM/ml), and may be diagnosed with T2D (blood glucose \>126 mg/dL).

Exclusion Criteria:

-pregnancy, lactation

Conditions6

Atherosclerotic Cardiovascular DiseaseAtherosclerotic PlaqueCardiac HypertrophyCardiovascular DiseaseHeart DiseasePCOS

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.